BOISE, Idaho (AP) — Idaho has reached a $2.6 million settlement with GlaxoSmithKline over accusations that the drug company accused sold products at false or inflated prices.
The agreement announced Tuesday marks the state’s 14th settlement over price fixing matters with drug companies since 2005.
Attorney General Lawrence Wasden says an investigation revealed the company inflated average wholesale prices of drugs eligible for Medicaid reimbursement by as much as 27 percent.
The inflated price results in overpayments to pharmacies that provide the drugs to Idaho Medicaid clients.
The settlement will return $620,000 to Idaho’s general fund and $1.5 million to the federal government, bringing the total recovered since 2005 to $20 million.
Three other cases naming eight other drug manufacturers are still pending.
